The authors of this study reviewed the TCGA database and identified MAP2K1 alterations in 7% of melanomas, consisting mostly of point mutations with some amplifications and no in-frame deletions, with nearly all co-occurring with BRAF or NRAS mutations [11]. The gene discussed is BRAF; the disease is melanoma.